Starting Foodtech in Israel PERIOD emerged from theft and reported that it obtained a GLP-1 edge, a bioactive peptide inducing GLP-1 and other gut hormones regulating appetite and metabolism. GLP-1 is Ozemptic basis. The company plan to offer the edge of GLP-1 as a pill as well as being with food as a type of “slimming food.”
The Company also announces that it has raised $ 3.6 million in a pre-seed financing round led by Flora Ventures, Fresh Fund, Longevity Venture Partners, Maia Ventures, Siddhi Capital, Mandi Ventures and Sdh.
Lembas was established in 2024 by Shay Hilel (CEO), Dr. Zohar Barbash (CTO), Prof. MAJA) and Dr. Daniel Bar with a significant impact on the health using AI, and the current product is its first.
GLP-1 is kept in the body naturally, after consumption of certain foods, such as foods high in fiber or protein. Injectable GLP-1 drugs have many higher doses of substance than the body’s secrets of itself. Lembas’s purpose is to find specific food components that can cause high Hide of GLP-1.
The GLP-1 drugs such as Ozemptic, Mounjaro and others in the market that is in progress, given by injecting a long dose for a long time. These drugs lead to an average weight loss of about 15%, now the minimum threshold for weight market competition.
There are oral medications achieving the lowest weight loss rate, and also regarded as important opponents because of their easier form of administration.
Lembas did not see its product as a direct competitor in injectable medications, but as a product that is appropriate for those who do not want to inject the medication or want to give up the medication and want to overcome weight. Recommendation is to replace a meal a day with a pill, or to food with supplement.
It is difficult to compare medications with the effectiveness of such a product, because regulation does not require a test of food products, but a self-test needed for food products. In animal models, companies handle to achieve two-thirds of the weight gained in “semaglutide”, the active component of ozemptic.
Related articles
Lembas hopes its products in the market of 2027, even if it depends on the agreements of food and supplement companies. Israel epitomee, developing a weight loss pill with a different mechanism, signing an agreement with the approval of product plots not attained in performance level. Lembas will face similar challenges when part of a convincing food companies that its product has a rapidly developing world of GLP.
Published in Globes, Israel News in News – en.globes.co.il – On June 22, 2025.
© Copyright in Globes Publisher Itonut (1983) Ltd., 2025.
